CA
NZ
UK
AU
IND
US
…
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Precigen Inc is a clinical-stage biotechnology company developing gene and cell therapies using engineered biological platforms, with pipeline programs focused on oncology and infectious disease. Long-term growth drivers include clinical advancement and potential regulatory approvals, strategic collaborations and licensing, and wider adoption of engineered therapeutic modalities, which may benefit investors seeking exposure to next-generation biologics.
Primary investment risks include clinical and regulatory failure, significant cash burn that may necessitate dilutive financing, and strong scientific and competitive pressures in the cell and gene therapy sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -250.64M | -128.03M | -96.36M | -79.97M | -96.92M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -250.64M | -126.23M | -95.90M | -79.78M | -96.77M |
| Selling general administrative | 70.13M | 41.29M | 40.41M | 48.01M | 74.12M |
| Gross profit | 3.59M | -0.34M | 0.11M | 20.57M | 45.49M |
| Reconciled depreciation | 3.20M | 4.53M | 6.67M | 10.77M | 13.76M |
| Ebit | -246.77M | -128.02M | -95.89M | -74.61M | -78.78M |
| Ebitda | -243.57M | -123.50M | -89.23M | -72.07M | -77.49M |
| Depreciation and amortization | 3.20M | 4.53M | 6.67M | 2.53M | 1.28M |
| Non operating income net other | - | - | - | 2.53M | 1.28M |
| Operating income | -106.60M | -135.03M | -99.76M | -74.61M | -78.78M |
| Other operating expenses | 116.28M | 138.95M | 105.98M | 101.52M | 182.65M |
| Interest expense | 3.87M | 0.01M | 0.47M | 6.77M | 18.89M |
| Tax provision | 0.00M | -1.79M | -0.46M | -0.19M | -0.16M |
| Interest income | 3.21M | 1.42M | 3.24M | 0.13M | 1.62M |
| Net interest income | -0.65M | 1.41M | 2.77M | -6.64M | -17.27M |
| Non recurring | - | - | - | 1.12M | 0.54M |
| Income tax expense | 0.00M | -1.79M | -0.46M | -0.19M | -0.16M |
| Total revenue | 9.68M | 3.92M | 6.22M | 26.91M | 103.87M |
| Total operating expenses | 110.19M | 134.69M | 99.86M | 95.18M | 124.26M |
| Cost of revenue | 6.10M | 4.27M | 6.12M | 6.34M | 58.38M |
| Total other income expense net | -144.04M | 7.00M | 3.40M | -5.36M | -18.15M |
| Discontinued operations | - | - | - | 108.09M | 4.60M |
| Net income from continuing ops | -250.64M | -126.23M | -95.90M | -79.78M | -96.77M |
| Net income applicable to common shares | - | - | - | 28.32M | -92.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 156.62M | 145.27M | 151.04M | 215.98M | 359.86M |
| Intangible assets | 3.18M | 4.46M | 40.70M | 44.45M | 54.12M |
| Other current assets | 3.43M | 3.34M | 4.33M | 4.78M | 6.74M |
| Total liab | 135.71M | 106.75M | 41.64M | 89.72M | 252.51M |
| Total stockholder equity | 20.91M | 38.51M | 118.50M | 126.26M | 107.35M |
| Deferred long term liab | - | - | - | - | 2.54M |
| Other current liab | 23.67M | 16.44M | 19.55M | 30.12M | 22.84M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -2341.35M | -2090.71M | -1964.47M | -1868.57M | -1915.56M |
| Other liab | - | - | - | 4.08M | 25.61M |
| Good will | 15.23M | 19.14M | 26.61M | 36.92M | 54.15M |
| Other assets | - | 68.39M | - | 1.02M | 1.19M |
| Cash | 30.23M | 29.52M | 7.58M | 4.86M | 42.92M |
| Total current liabilities | 37.31M | 21.52M | 22.98M | 78.64M | 34.65M |
| Current deferred revenue | 0.52M | 0.59M | 0.51M | 0.03M | 4.44M |
| Net debt | 68.06M | -24.02M | -0.48M | 46.56M | 151.28M |
| Short term debt | 1.14M | 0.96M | 1.20M | 44.43M | 1.95M |
| Short long term debt | - | - | - | 43.22M | 0.40M |
| Short long term debt total | 98.29M | 5.50M | 7.10M | 51.42M | 194.20M |
| Other stockholder equity | 2362.25M | 2129.21M | 2086.86M | 1998.31M | 2022.70M |
| Property plant equipment | - | - | - | 7.33M | 45.22M |
| Total current assets | 115.23M | 102.41M | 68.75M | 118.16M | 156.63M |
| Long term investments | 2.51M | 0.00M | - | 0.00M | 48.56M |
| Net tangible assets | - | - | - | 126.26M | -0.92M |
| Short term investments | 67.62M | 68.39M | 55.28M | 51.09M | 72.24M |
| Net receivables | 4.36M | 1.16M | 1.57M | 13.80M | 21.47M |
| Long term debt | 93.17M | - | - | - | 182.75M |
| Inventory | 9.58M | 0.00M | 0.00M | 0.29M | 13.26M |
| Accounts payable | 11.98M | 3.53M | 1.73M | 4.07M | 5.41M |
| Accumulated other comprehensive income | 0.01M | 0.01M | -3.89M | -3.49M | 0.20M |
| Retained earnings total equity | - | - | - | -1868.57M | -1915.56M |
| Non currrent assets other | 0.91M | 0.46M | -8.60M | 1.02M | 1.19M |
| Non current assets total | 41.39M | 42.85M | 82.29M | 97.82M | 203.23M |
| Capital lease obligations | 5.12M | 5.50M | 7.10M | 8.20M | 11.05M |
| Long term debt total | - | - | - | - | 182.75M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.46M | -20.71M | -3.09M | 68.44M | -74.05M |
| Change to liabilities | - | - | - | 11.79M | 2.08M |
| Total cashflows from investing activities | -1.53M | -20.71M | -3.09M | 226.42M | -74.54M |
| Net borrowings | 92.82M | 0.00M | -43.22M | -155.29M | -0.47M |
| Total cash from financing activities | 90.05M | 110.58M | 29.59M | -155.29M | 121.19M |
| Change to operating activities | - | - | - | 0.21M | 5.20M |
| Net income | -250.64M | -126.23M | -95.90M | 28.32M | -92.17M |
| Change in cash | 0.72M | 21.67M | -40.75M | 5.25M | -8.91M |
| Begin period cash flow | 29.52M | 7.85M | 48.60M | 43.34M | 52.25M |
| End period cash flow | 30.23M | 29.52M | 7.85M | 48.60M | 43.34M |
| Total cash from operating activities | -87.83M | -68.17M | -66.93M | -65.05M | -55.77M |
| Issuance of capital stock | - | 110.24M | 72.81M | 0.00M | 121.05M |
| Depreciation | 3.20M | 4.53M | 6.67M | 10.77M | 13.76M |
| Other cashflows from investing activities | -1.53M | 0.06M | 0.10M | 162.90M | 3.75M |
| Change to inventory | -9.21M | 0.00M | 0.00M | 2.34M | -1.90M |
| Change to account receivables | -3.20M | 0.41M | 12.23M | -2.23M | -6.18M |
| Sale purchase of stock | -2.20M | 0.00M | 0.00M | 0.00M | 0.61M |
| Other cashflows from financing activities | -3.08M | 79.35M | -3.09M | -0.59M | 0.61M |
| Change to netincome | - | - | - | 10.82M | 11.70M |
| Capital expenditures | 2.00M | 8.58M | 1.54M | 4.92M | 7.25M |
| Change receivables | - | - | - | -13.51M | -6.56M |
| Cash flows other operating | - | - | - | -117.44M | -2.68M |
| Cash and cash equivalents changes | - | - | - | 6.08M | -9.12M |
| Change in working capital | 6.62M | 4.52M | 17.07M | -22.70M | -0.80M |
| Stock based compensation | 10.87M | 9.47M | 9.89M | 10.21M | 13.90M |
| Other non cash items | 142.12M | 41.34M | -4.17M | -91.48M | 9.70M |
| Free cash flow | -89.83M | -76.76M | -68.47M | -69.97M | -63.02M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PGEN Precigen Inc |
-0.46 8.67% |
4.79 | - | 15.58 | 29.24 | 56.28 | 29.31 | -3.31 |
| NVO Novo Nordisk A/S |
2.50 6.23% |
42.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.96 0.18% |
531.72 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-6.27 0.64% |
967.09 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876
301 556 9900
160
| Name | Title | Year Born |
|---|---|---|
| Mr. Randal J. Kirk J.D. | Exec. Chairman | 1953 |
| Dr. Helen Sabzevari MPH, Ph.D. | Pres, CEO & Director | 1962 |
| Mr. Harry Thomasian Jr. | Chief Financial Officer | 1962 |
| Mr. Donald P. Lehr | Chief Legal Officer & Corp. Sec. | 1975 |
| Mr. Jeffrey Thomas Perez | Sr. VP of Intellectual Property Affairs | 1972 |
| Dr. Thomas D. Reed | Founder & Chief Science Officer | 1966 |
| Mr. Rutul R. Shah | Chief Operating Officer | NA |
| Mr. Steven Harasym | VP & Head of Investor Relations | NA |
| Marie Rossi | VP of Communications | NA |
| Mr. Rob Russell | VP & Head of HR | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.92%
Communication Services
+1.33%
Consumer Cyclical
+1.45%
Consumer Defensive
+0.54%
Energy
-1.28%
Financial Services
+0.74%
Financials
+0.21%
Healthcare
+1.04%
Industrials
+0.14%
Real Estate
+0.65%
Technology
+1.12%
Utilities
+0.37%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...